Loading the section…

CDNA: financial statements from SEC — TradeAlmanac

CDNA

CareDx, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/03/2026	30/09/2025	30/06/2025	31/03/2025	30/09/2024	30/06/2024
Revenue	118M	100M	87M	85M	83M	92M
Research and development	21M	17M	17M	19M	17M	20M
Selling, general and administrative	30M	28M	28M	23M	32M	31M
Operating expenses	117M	100M	98M	98M	97M	100M
Operating income	1M	−246,000	−11M	−13M	−14M	−7M
Pre-tax income	3M	2M	−9M	−10M	−10M	−5M
Income tax	−32,012	−15,000	−117,000	58,000	200,000	22,000
Net income	3M	2M	−9M	−10M	−11M	−5M
Earnings per share	0.05	0.03	−0.16	−0.19	−0.20	−0.09
Earnings per share, diluted	0.05	0.03	−0.16	−0.19	−0.20	−0.09
Weighted average shares	51M	53M	54M	55M	53M	52M
Weighted average shares, diluted	53M	54M	54M	55M	53M	52M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	78M	65M	91M	68M	89M	115M	95M	96M
Short-term investments	109M	112M	103M

Cash flow

Metric	31/03/2026	31/03/2025
Operating cash flow	4M	−27M
Depreciation and amortisation	4M	4M
Share-based compensation	10M	9M
Capital expenditure	4M	2M
Investing cash flow	11M	1M
Share buybacks	—

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator